Vericel Corporation has delivered four consecutive quarterly earnings beats with 30% year-over-year revenue growth and a Rule of 40 score of 45, positioning it as a high-growth regenerative medicine company, though a 13% short interest and 110% implied volatility signal elevated speculative risk.
Thesis pillars
- Consecutive Earnings Beat Streak↓Deteriorating
- Rule Of 40 Growth Quality→Stable
- Supplier Concentration Pipeline Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026
Vericel Corporation (VCEL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $41.09, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel GmbH; Concentration risk — Supplier: MediWound.
Vericel Corporation sells three FDA-approved products in the U.S. — MACI for knee cartilage repair, Epicel for permanent skin replacement in severe burns, and NexoBrid for eschar removal — targeting orthopedic surgeons and burn centers. Revenue comes through specialty pharmacy... Read more
Hold if already holding. Not a fresh buy at $41.09, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel GmbH; Concentration risk — Supplier: MediWound. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Maintain position. Not compelling to add more. Score 6.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: speculative.
About Vericel Corporation
About Vericel Corporation
Three FDA-approved products define Vericel Corporation's commercial portfolio: MACI for knee cartilage repair (BLA approved December 2016, arthroscopic indication added August 2024), Epicel for full-thickness burns covering ≥30% total body surface area, and NexoBrid for eschar removal in adult and pediatric patients (pediatric BLA expanded August 2024). Net income was $16.5 million for the year ended December 31, 2025, the company's second consecutive profitable year after losses at inception.
Vericel generates revenue through three distinct commercial channels. MACI is dispensed via a limited network of specialty pharmacy distributors — primarily Orsini and AllCare — with credit and collection risk borne by Vericel under those distribution agreements; a portion of MACI implants is also sold directly to facilities at contracted purchase order prices. Epicel and NexoBrid are sold directly to burn centers and hospitals at contracted rates, with hospitals billing third-party payers through capitated or global payment structures. Manufacturing for MACI and Epicel occurs at Vericel's Cambridge, Massachusetts facility, with a Burlington facility in qualification to become the primary site; NexoBrid is manufactured by MediWound in Israel using the active ingredient bromelain sourced from Taiwan. Following the August 2024 MACI Arthro launch, the company expanded its target surgeon base from 5,000 to 7,000, and more than 900 surgeons had participated in Company-sponsored arthroscopic training programs.
Show full overview
Two named sole-source manufacturing dependencies run through Vericel's supply chain. ACI-Maix collagen membranes required for MACI production are supplied exclusively by Matricel GmbH under an agreement effective through December 31, 2030 — the 10-K notes that if Matricel cannot supply membranes, Vericel may need to license the technology and procure from an alternate source, a process with no guaranteed timeline. NexoBrid's manufacture occurs at MediWound's facilities in Israel with bromelain sourced from Taiwan, exposing the burn care franchise to dual geopolitical risk vectors — Middle East instability and China-Taiwan tensions — cited explicitly in the 10-K.
See also: Healthcare · Biotechnology
From Vericel Corporation's most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-10-29Recent Developments — Vericel Corporation
Latest news
- NEWS VCEL|Vericel Corp|Price:46.700|Chg%:+1.380 - TradingKey — TradingKey neutral
- NEWS VCEL (Vericel Corporation) reports 13.1 percent Q4 2025 EPS beat, shares fall 6.23 percent in today’s trading. - Earning — Newser positive
- NEWS Vericel (VCEL) Q1 2026 Earnings: EPS Beats Expectations as Loss Narrows - Earnings Weakness Phase - dars.gov.et — dars.gov.et positive
- NEWS Vericel (VCEL) Q1 2026 Earnings: EPS Beats Expectations as Loss Narrows - Net Income Trends - dars.gov.et — dars.gov.et positive
- NEWS Vericel (VCEL) Q1 2026 Earnings: EPS Beats Expectations as Loss Narrows - Revenue Inflection Point - dars.gov.et — dars.gov.et positive
Generated 2026-10-29T11:08:52Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierMatricel GmbH10-K Item 1: 'The Matricel Supply Agreement provides that Matricel will supply the ACI-Maix membranes exclusively to us during the term of the agreement.'
- HIGHSupplierMediWound10-K Item 1: 'we have held exclusive license and supply agreements with MediWound ... The manufacturing process for NexoBrid is conducted by MediWound'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $41.09, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: Matricel GmbH; Concentration risk — Supplier: MediWound. Chart setup: Golden cross, above all MAs, RSI 56, MACD bullish. Maintain position. Not compelling to add more. Analyst target $51.95 (+26.4%), stop $38.21 (−7.5%), A.R:R 3.7:1. Score 6.2/10, moderate confidence.
Analyst target: $51.95 (+26.4% upside). Analyst target $51.95 (+26.4%), stop $38.21 (−7.5%), A.R:R 3.7:1. Stop-loss: $38.21.
Concentration risk — Supplier: Matricel GmbH; Concentration risk — Supplier: MediWound; Earnings in 6 days (event risk).
Vericel Corporation trades at a P/E of 87.4 (forward 48.6). TrendMatrix value score: 5.4/10. Verdict: Hold.
14 analysts cover VCEL with a consensus score of 4.2/5. Average price target: $60.
What does Vericel Corporation do?Vericel Corporation sells three FDA-approved products in the U.S. — MACI for knee cartilage repair, Epicel for...
Vericel Corporation sells three FDA-approved products in the U.S. — MACI for knee cartilage repair, Epicel for permanent skin replacement in severe burns, and NexoBrid for eschar removal — targeting orthopedic surgeons and burn centers. Revenue comes through specialty pharmacy distributors for MACI and direct hospital sales for Epicel and NexoBrid; the company reported net income of $16.5 million in 2025.